Catalyst Wire Dossier Catalyst Wire Dossier

Ryzodeg 70/30

insulin degludec/insulin aspart · Novo Nordisk A/S
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Ryzodeg 70/30, covering 2015-11-17 to 2015-11-20. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens [Phase 3]

See pricing